Monitoring Agency Report for the quarter ended June 30, 2026

Registered & Corporate Office: AMANTA HEALTHCARE LIMITED 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat, INDIA. Tel.: 079 – 67777600 Email: info@amanta.co.in Website: www.amanta.co.in CIN: L24139GJ1994PLC023944 August 8, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G Phiroze Jeejeebhoy Towers, Bandra Kurla Complex Dalal Street, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Scrip Code: 544502 Trading Symbol: AMANTA Dear Sir/ Madam, Sub: Monitoring Agency Report for the quarter ended June 30, 2026 Pursuant to Regulation 32(6) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed the Monitoring Agency Report issued by CRISIL Ratings Limited, the Monitoring Agency, in respect of the utilization of the fund raised through public issue by the company for the quarter ended June 30, 2026. The above is being made available on the Company’s website at www.amanta.co.in Kindly take the same on your records. Thanking you. Yours sincerely, For AMANTA HEALTHCARE LIMITED NIKHITA DINODIA Company Secretary & Compliance Officer Encl.: As above Factory: 876, N.H. No. 8, Hariyala, Kheda – 387411, Gujarat, India. Tel 2694287700 Fax 2694287720 Monitoring Agency Report Amanta Healthcare Limited for the quarter ended June 30, 2026 CRL/MAR/MBL/2026-27/1935 August 07, 2026 Amanta Healthcare Limited 8th Floor, Shaligram Corporates, C.J. Marg, Ambli, Ahmedabad – 380058, Gujarat, Dear Sir/Madam, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Initial Public Offer (“IPO”) of Amanta Healthcare Limited (“the Company”) Pursuant to Regulation 41 of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and Monitoring Agency Agreement dated August 21, 2025, enclosed herewith the Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of IPO for the quarter ended June 30, 2026. Request you to kindly take the same on records. Thanking you, For and on behalf of Crisil Ratings Limited Shounak Chakravarty Director, Ratings (LCG) Report of the Monitoring Agency (MA) Name of the issuer: Amanta Healthcare Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: Crisil Ratings Limited (a) Deviation from the objects: Not applicable (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Shounak Chakravarty Designation of Authorized person/Signing Authority: Director, Ratings (LCG) 1) Issuer Details: Name of the issuer: Amanta Healthcare Limited Names of the promoter: Mr. Bhavesh Girishbhai Patel Mrs. Jayshreeben Rohitkumar Patel Mr. Vishal Ashokkumar Patel Mr. Jitendrakumar Jashbhai Patel Industry/sector to which it belongs: Pharmaceuticals 2) Issue Details Issue Period: Monday, September 01, 2025 to Wednesday, September 03, 2025 Type of issue (public/rights): Initial Public Offer (IPO) Type of specified securities: Equity Shares IPO Grading, if any: NA Issue size: Rs 12,600.00 lakhs (Refer Note 1) Note 1: Particulars Amount (Rs in lakhs) Gross proceeds of the Fresh Issue 12,600.00# Less: Issue Expenses 2,284.81 Net Proceeds 10,315.19$ #Crisil Ratings shall be monitoring the gross proceeds. $During the quarter ended September 30, 2025, net proceeds have been revised from Rs 10,673.57 lakhs to Rs 10,315.19 lakhs, on account of actual issue expenses being higher than estimated as disclosed in the Prospectus, by Rs 358.38 lakhs and the same has been adjusted with General corporate purposes cost. 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information/ certifications Comments of Comments of the Particulars Reply considered by the Board of Monitoring Agency Monitoring Agency Directors for preparation of report Management undertaking, Peer reviewed independent chartered accountant Proceeds were utilized Whether all utilization is as per the certificate^, towards funding Yes No Comments disclosures in the Offer Document? Prospectus dated capital expenditure September 04, 2025 requirements (hereinafter referred as “Offer document”), Bank Statements Whether shareholder approval has been obtained in case of material NA No Comments No Comments deviations from expenditures disclosed in the Offer Document? Whether the means of finance for the disclosed objects of the issue has No No Comments No Comments changed? Is there any major deviation observed over the earlier No No Comments No Comments monitoring agency reports? Whether all Government/statutory approvals related to the object(s) NA Management No Comments No Comments have been obtained? undertaking, Peer reviewed independent Whether all arrangements chartered accountant pertaining to technical NA certificate^ No Comments No Comments assistance/collaboration are in operation? Are there any favorable events improving the viability of these No No Comments No Comments object(s)? Are there any unfavorable events affecting the viability of the No No Comments No Comments object(s)? Is there any other relevant information that may materially No No Comments No Comments affect the decision making of the investors? NA represents Not Applicable ^Certificate dated July 27, 2026, issued by M/s S G D G & Associates. LLP, Chartered Accountants (Firm Registration Number: W100188), peer reviewed independent chartered accountant. 4) Details of object(s) to be monitored: i. Cost of the object(s): Original Comments of the Board of Source of cost Directors information/ (as per the Revised Comment certification Particulars Sr. Offer Cost of the Reason Item considered by Proposed of fi [Showing first 8,000 characters — download PDF for full document]